Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its ...

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

For Vertex, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its newly launched ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

Neurocrine Biosciences, Inc. today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial ...

Vertex Pharmaceuticals is prepping for its Q1 earnings reveal on May 5, with analysts expecting mixed results. EPS is ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

The stock's fall snapped a seven-day winning streak.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...